Ad-hoc | 4 July 2017 00:23
STADA Arzneimittel AG confirms that Bain Capital and Cinven are considering to apply for an exemption from one-year exclusion period for the submission of a renewed voluntary public takeover offer
|
STADA Arzneimittel AG / Key word(s): Miscellaneous
Bad Vilbel, July 3, 2017 – STADA Arzneimittel AG confirms that Nidda Healthcare Holding AG, the acquiring company of Bain Capital and Cinven, gave notice to be considering to submit an application to the German Federal Financial Supervisory Authority (BaFin) for an exemption from the one-year exclusion period to make a renewed voluntary public takeover offer under section 26(2) of the German Securities Acquisition and Takeover Act (WpÜG). STADA is currently assessing whether the company would give its consent to the exemption from the exclusion period and will keep both the capital market and the public updated on further progress in this regard, in line with the applicable legal requirements.
Or visit us on the internet at www.stada.com
04-Jul-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|
| Language: | English |
| Company: | STADA Arzneimittel AG |
| Stadastraße 2-18 | |
| 61118 Bad Vilbel | |
| Germany | |
| Phone: | +49 (0)6101 603- 113 |
| Fax: | +49 (0)6101 603- 506 |
| E-mail: | communications@stada.de |
| Internet: | www.stada.de |
| ISIN: | DE0007251803, DE0007251845, |
| WKN: | 725180, 725184, |
| Indices: | MDAX |
| Listed: | Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| End of Announcement | DGAP News Service |